• Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma

  • Oct 30 2024
  • Length: 15 mins
  • Podcast

Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma

Listen for free

View show details

  • Summary

  • Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma.

    Read the full Articles here:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00502-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00503-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Tell us what you thought about this episode

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available